Disposition of 57273 shares by Jonathan Schwartz of Rocket Pharmaceuticals at 30.01 subject to Rule 16b-3

RCKT Stock  USD 14.39  0.19  1.34%   
Slightly above 61% of all Rocket Pharmaceuticals' private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Rocket Pharmaceuticals suggests that some traders are interested. Rocket Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Rocket Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Rocket Pharmaceuticals Officer See Remarks. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 57273 stock option (right to buy) at 30.01 of Rocket Pharmaceuticals by Jonathan Schwartz on 8th of September 2024. This event was filed by Rocket Pharmaceuticals with SEC on 2025-02-16. Initial filing of beneficial ownership - SEC Form 3

Cash Flow Correlation

Rocket Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Rocket Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Rocket Pharmaceuticals Fundamental Analysis

We analyze Rocket Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Per Share

Cash Per Share Comparative Analysis

Rocket Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Rocket Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rocket Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Rocket Pharmaceuticals Related Equities

MGTXMeiraGTx Holdings   3.36   
0%
71.0%
PLRXPliant Therapeutics   2.00   
0%
42.0%
STOKStoke Therapeutics   1.68   
0%
35.0%
DAWNDay One   1.53   
0%
32.0%
SNDXSyndax Pharmaceuticals   1.27   
0%
27.0%
PCVXVaxcyte   0.38   
0%
8.0%
REPLReplimune   0.21   
0%
4.0%
SLDBSolid Biosciences   0.18   
0%
3.0%
MRUSMerus BV   0.29   
6.0%
0%
RYTMRhythm Pharmaceuticals   0.34   
7.0%
0%
INZYInozyme Pharma   0.37   
7.0%
0%
CYTKCytokinetics   0.69   
14.0%
0%
QUREUniqure NV   0.83   
17.0%
0%
RGNXRegenxbio   0.90   
19.0%
0%
MIRMMirum Pharmaceuticals   0.92   
19.0%
0%
RVMDRevolution Medicines   1.25   
26.0%
0%
VRDNViridian Therapeutics   1.46   
31.0%
0%
STROSutro Biopharma   1.49   
31.0%
0%
DYNDyne Therapeutics   1.67   
35.0%
0%
LRMRLarimar Therapeutics   4.67   
100.0%
0%

Additional Tools for Rocket Stock Analysis

When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.